MacroGenics, Inc.
9704 Medical Center Drive
Rockville
Maryland
20850
United States
Tel: 301-354-3758
Website: https://macrogenics.com/capabilities/
Email: collaborate@macrogenics.com
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company developing and manufacturing a portfolio of innovative antibody-based products intended to extend and enhance the lives of people with cancer. We achieve this by leveraging the skills, passion, and scientific expertise of our employees and partners. Part of this mission includes providing our expertise in biopharmaceutical development and manufacturing to CDMO clients via our FDA-licensed commercial manufacturing facility. Our GMP suite utilizes single-use technology for maximum speed and flexibility and is outfitted for production of mammalian drug substance at the 500 L or 2000 L scale. In addition to manufacturing, we offer a fully customizable CDMO package with optional development services and analytical testing.
MacroGenics is committed to redefining CDMO relationships through efficient collaboration, client prioritization and transparency. Ensuring your values align with our company culture is as important to us as ensuring your process fits our facility.
If you are interested in learning more about our CDMO capabilities, come check us out in Rockville, Maryland! Reach out to schedule a meeting and tour of our facility to discuss your CDMO needs.
Stock Symbol: MGNX
Stock Exchange: NASDAQ
256 articles about MacroGenics, Inc.
-
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial ResultsConference call scheduled for today at 4:30 p.m. ET
11/6/2019
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended September 30, 2019.
-
MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019
11/6/2019
MacroGenics, Inc. announced the clinical and preclinical abstracts related to flotetuzumab, the Company’s investigational bispecific CD123 x CD3 DART® molecule, to be presented at the 61st American Society of Hematology Annual Meeting & Exposition in Orlando, Florida, from December 7-10, 2019.
-
To wrap up Breast Cancer Awareness Month, BioSpace gathered some examples of recent breakthroughs in breast cancer treatment.
-
MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
10/30/2019
MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company will release its financial results for the third quarter of 2019 after the market closes on Wednesday, November 6, 2019.
-
Clinical Catch-Up: October 21-25
10/28/2019
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look. -
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
10/25/2019
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2/3 MAHOGANY clinical trial of margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2
-
MacroGenics’ metastatic HER2-positive breast cancer treatment margetuximab continues to show promise following a second pre-planned interim overall survival analysis of its Phase III SOPHIA trial.
-
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
10/22/2019
MacroGenics, Inc. announced topline results from the second pre-specified interim overall survival analysis for the Phase 3 SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.
-
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
7/10/2019
MacroGenics, Inc. (NASDAQ: MGNX), and I-Mab Biopharma (I-Mab), a China and U.S.-based clinical-stage biopharmaceutical company committed to the discovery and development of first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, announced today that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab.
-
Here's a roundup of some of the top clinical trial news from the previous week.
-
The trial evaluated margetuximab in patients with HER2-positive metastastic breast cancer who had already been treated with anti-HER2-targeted therapies.
-
Shares of Rockville, Md.-based MacroGenics, Inc. have skyrocketed nearly 160 percent in premarket trading after the company announced its Phase III HER2-positive metastatic breast cancer study hit the mark.
-
Trianni, Inc. and MacroGenics, Inc. Announce License Agreement
12/6/2018
Trianni, Inc. and MacroGenics, Inc. today announced that they have entered into a license agreement for The Trianni Mouse™, a best-in-class transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support MacroGenics' discovery programs for monoclonal antibody-based therapeutics for the treatment of cancer.
-
MacroGenics to Present at Wedbush PacGrow Healthcare Conference
8/9/2018
MacroGenics, Inc.. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at the 2018 Wedbush PacGrow Healthcare Conference in New York on Tuesday, August 14, 2018 at 10:20 am (ET).
-
MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results
8/7/2018
MacroGenics, Inc. provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2018.
-
MacroGenics Announces Date of Second Quarter 2018 Financial Results Conference Call
7/30/2018
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, August 7, 2018, the Company will release its financial results for the quarter ended June 30, 2018. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Tuesday, August 7, 2018 at 4:30 pm (ET).
-
Provention Bio Announces Agreements with MacroGenics for Two Clinical-Stage Assets for the Treatment of Autoimmune Disorders
5/9/2018
Provention acquires PRV-031 and plans to initiate pivotal Phase 3 clinical trial to intercept early-onset type 1 diabetes, a pediatric orphan indication
-
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
1/24/2018
FDA grants Fast Track designation to margetuximab for treatment of metastatic breast cancer.
-
In the deal, both companies will leverage their respective platforms, including MacroGenics’ DART platform and Roche’s CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.
-
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement With Incyte
12/6/2017
Under the deal, MacroGenics will receive an upfront payment of $150 million, while Incyte receives worldwide rights to develop and commercialize MGA012 in all indications.